Emricasan™, a caspase inhibitor for liver diseases
The founding team of Conatus re-acquired Emricasan™, a caspase inhibitor for reducing apoptosis and inflammation in the treatment of liver diseases. Emricasan™ is a hepatoprotectant arresting the rate of deterioration of liver function. It is in several Phase II clinical studies for a number of liver diseases.
CEO Steven J. Mento
Advent invested in the Series A in 2006. Conatus listed on NASDAQ in 2013 (NASDAQ:CNAT).
Conatus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
Press Release. San Diego, CA – July 25, 2013 – Conatus Pharmaceuticals Inc., a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease,…Read More